2019
Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms
Ohmori Y, Nomura T, Fukushima N, Takahashi F, Iwaya T, Koeda K, Nishizuka S, Consortium M. Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms. Journal Of Surgical Oncology 2019, 120: 1154-1161. PMID: 31578743, DOI: 10.1002/jso.25718.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCodonFemaleFollow-Up StudiesGastrectomyGenetic Predisposition to DiseaseGenotypeHumansIncidenceJapanMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPolymorphism, Single NucleotideRisk AssessmentStomach NeoplasmsSurvival RateTumor Suppressor Protein p53ConceptsRelapse-free survivalTP53 codon 72 polymorphismArg/ArgCodon 72 polymorphismGastric cancerOverall survivalHazard ratioHigh-risk patient groupsPostoperative adjuvant chemotherapyRecurrence risk evaluationArg/ProPro/Pro groupAdjuvant chemotherapyT3N0M0 patientsCurative intentStudy cohortPatient groupPro polymorphismEntire observation periodPolymorphism statusPRO groupPatientsArg/CancerPro/
2013
Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer
Iwaya T, Fukagawa T, Suzuki Y, Takahashi Y, Sawada G, Ishibashi M, Kurashige J, Sudo T, Tanaka F, Shibata K, Endo F, Katagiri H, Ishida K, Kume K, Nishizuka S, Iinuma H, Wakabayashi G, Mori M, Sasako M, Mimori K. Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer. Clinical Cancer Research 2013, 19: 6438-6449. PMID: 24097871, DOI: 10.1158/1078-0432.ccr-12-3186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorBone MarrowCell Line, TumorFemaleGastric MucosaGene Expression Regulation, NeoplasticHistonesHumansKaplan-Meier EstimateLymphatic MetastasisMaleMicroRNAsMiddle AgedMultivariate AnalysisNeoplasm StagingOligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsRNA InterferenceRNA, MessengerSequence Analysis, RNAStomach NeoplasmsTranscriptomeConceptsGastric cancer patientsStage IV patientsStage I patientsCancer patientsBone marrow samplesIV patientsBone marrowMiR-760 expressionPrimary tumor samplesPrimary tumorGastric cancerMiR-760I patientsPeripheral bloodMarrow samplesStage IV gastric cancer patientsAdvanced gastric cancer patientsTumor samplesLuciferase reporter assaysNoncancerous cellsRNA-seq analysisPrognostic markerMicroRNA-760Noncancerous mucosaPatientsEvaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer
Matsuo T, Nishizuka SS, Ishida K, Endo F, Katagiri H, Kume K, Ikeda M, Koeda K, Wakabayashi G. Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer. World Journal Of Surgical Oncology 2013, 11: 11. PMID: 23339659, PMCID: PMC3562164, DOI: 10.1186/1477-7819-11-11.Peer-Reviewed Original ResearchConceptsDose-response curveChemosensitivity testGastric cancerResistant cancer cell populationsStandard chemotherapy regimensPeak plasma concentrationDose-response patternDrug dose-response curvesPrimary chemotherapyChemotherapy regimensRecurrent diseaseStandard chemotherapyResultsA totalChemosensitivity evaluationPlasma concentrationsChemosensitivity patternsChemoresistant tumorsResistant patternChemotherapyDrug resistanceDrug sensitivityCancer cell populationsConclusionsThese resultsCisplatinCell populations